BRAF and central nervous system cancer: It has been shown that the BRAF V600E mutation was found in nearly 20% of low-grade glioma patients [15–17] and this alteration may play an oncogenic role by constitutively activating the mitogen-activated protein kinase (MAPK) signaling pathway (also known as the RAS/RAF/MEK/ERK pathway).